Learning outcomes
By the end of this lesson you should be able to: list the hallmarks of cancer and give one molecular example of each; distinguish an oncogene from a tumour suppressor gene by the logic of its mutation; explain how loss of DNA repair accelerates tumour formation; describe the Warburg effect and why it matters clinically; and set out the classic genetic sequence of colorectal cancer as a model of multistep carcinogenesis.
Prerequisites
Lesson 10 (definitions and nomenclature) and lesson 1 (cell injury). You need the cell cycle, apoptosis and the signalling cascades from physiology and biochemistry (BCHM 101, modules on signal transduction and DNA replication) to follow the molecular detail.
The big idea
A cancer is not a cell that divides faster. A cancer is a cell that has acquired a set of capabilities, one mutation at a time, which together convert a law-abiding cell of a tissue into an autonomous, immortal, invasive, mobile and invisible-to-the-immune-system organism in its own right. Hanahan and Weinberg expressed this as the hallmarks of cancer, and the framework is worth more than any list of genes, because every gene name in the pathology textbooks maps onto one of these capabilities.
| Hallmark | What the cell gains | Example gene or mechanism |
|---|---|---|
| Sustained proliferative signalling | It no longer waits for an external growth signal — it makes its own | KRAS and BRAF mutations, HER2 amplification, autocrine growth factor loops |
| Evading growth suppressors | It ignores the tissue's stop signals from homeostatic mechanisms | Loss of RB (retinoblastoma) and TP53 |
| Resisting cell death | Apoptosis is one mechanism by which the body removes an abnormal cell — this fault in its function is lost | BCL2 overexpression, loss of TP53 |
| Enabling replicative immortality | Normal cells run out of telomeres and senesce; the cancer cell reactivates telomerase | TERT promoter mutation, telomerase reactivation |
| Inducing angiogenesis | It recruits and builds its own blood supply | VEGF secretion and its receptor switching off the anti-angiogenic side |
| Activating invasion and metastasis | It detaches, crosses the basement membrane, and travels and colonises | Loss of E-cadherin, matrix metalloproteinase induction, epithelial-to-mesenchymal transition |
| Reprogramming energy metabolism | It reroutes metabolism to fuel rapid growth | The Warburg effect — aerobic glycolysis even when oxygen is present |
| Evading immune destruction | It hides from, suppresses, or exhausts the T cells and natural killer cells that would remove it | PD-L1 expression, loss of antigen presentation, an immunosuppressive tumour microenvironment |
| Genome instability | It accumulates mutations at a higher rate than a normal cell, which accelerates all of the above | BRCA1/2 mismatch repair defects — hereditary non-polyposis colorectal cancer (HNPCC/Lynch) |
| Tumour-promoting inflammation | It hijacks the inflammatory infiltrate, turning macrophages and neutrophils into suppliers of growth and invasion factors | IL-6, TNF, chemokines from tumour-associated macrophages |
NoteThree of these hallmarks are drug targets in cancer therapy today: VEGF is the target of bevacizumab, the HER2 receptor is the target of trastuzumab, and the PD-1/PD-L1 interaction is the target of checkpoint inhibitors (pembrolizumab, nivolumab). Knowing the hallmark is how you know what the drug does.
The gene families
The hallmarks are acquired by mutations in four broad classes of gene, and the logic of each class is different. Learn the logic and the examples follow.
| Class | Mutation logic | Representative genes | Associated tumours |
|---|---|---|---|
| Oncogenes | Gain of function: one mutated allele is enough, and the mutation activates the protein | KRAS, MYC, HER2, BRAF, TERT | Pancreatic and colorectal carcinoma (KRAS), breast carcinoma (HER2), Burkitt lymphoma (MYC) |
| Tumour suppressors | Loss of function: both alleles must be hit, because the normal gene product restrains growth | TP53, RB, APC, BRCA1, BRCA2 | Li-Fraumeni and most cancers (TP53), retinoblastoma (RB), familial adenomatous polyposis (APC), breast and ovarian carcinoma (BRCA1/2) |
| DNA repair genes | Loss of function: errors in replication accumulate, so mutation rate rises (a mutator phenotype) | BRCA1/2, mismatch repair genes (MLH1, MSH2), XP protein genes | Hereditary breast and ovarian cancer, Lynch syndrome, xeroderma pigmentosum |
| Apoptosis regulators | Balance between the pro- and anti-apoptotic members is shifted | BCL2 (anti-apoptotic, amplified in follicular lymphoma), TP53 (pro-apoptotic) | Follicular lymphoma, many carcinomas |
This explains why cancer is clonal and why cancer increases with age: each division carries a chance of mutation, and mutations accumulate in the descendants that carry them. It also explains inheritance: inheriting one defective tumour suppressor allele means only a single somatic event in the other allele is needed in any cell — so hereditary cancers appear earlier, and in more than one site, than their sporadic counterparts.
Watch outMost cancers are not inherited. Monogenic inherited cancer syndromes account for a small minority; the common cancers are the result of somatic mutations accumulated over decades, modulated by environment. Familial clustering of common cancers, like breast and colorectal, is a mix of shared environment, low-penetrance variants and the rare strong syndromes.
Worked example: the Vogelstein sequence
The colorectal cancer sequence is the textbook model of multistep carcinogenesis, because it shows that each step is a loss of a specific control rather than a single leap to malignancy. It begins in a normal mucosa, and it progresses through a morphologically visible sequence of increasingly abnormal epithelium.
| Stage | Morphology | Genetic event |
|---|---|---|
| 1 | Normal mucosa | None |
| 2 | Hyperplastic epithelium | Loss of APC (the gatekeeper of the Wnt pathway) |
| 3 | Early adenoma | KRAS activation (gain of function of a growth signalling gene) |
| 4 | Intermediate adenoma | Loss of 18q (the DCC region, a tumour suppressor) |
| 5 | Late adenoma | Loss of TP53 (the guardian of the genome) |
| 6 | Invasive carcinoma | The accumulated hallmarks let it invade and metastasise |
Read the model as the answer to the question of why cancer takes years. A mutation in a growth suppressor is not enough; a growth-signalling oncogene is not enough; the cell has to lose the machinery of checkpoints and repair before the balance can tip. This is also the biological basis of polyp surveillance in familial adenomatous polyposis: removing the adenomas removes the substrate of the sequence.
Invasion and metastasis
Invasion and metastasis are a sequence, not a property, and each step can fail. The tumour cells lose the adhesion molecules that hold them to their neighbours — classically E-cadherin — and acquire the ability to cross the basement membrane by secreting matrix metalloproteinases that digest the surrounding stroma. They enter lymphatics and blood vessels, survive a circulation that would normally kill them (anchorage-independent survival, evasion of shear forces and of immune cells), arrest in a distant vascular bed, extravasate, and finally grow — in a microenvironment that may or may not support them. The molecular machinery behind this transformation is called epithelial-to-mesenchymal transition, and the cell that executes it gains motility at the cost of its differentiated function.
Why are most metastases in the first capillary bed downstream of the tumour — lung for most solid tumours, and liver for gut tumours?
Tumour heterogeneity
A tumour is not a uniform population of identical cells. Genomic instability and clonal evolution mean that subclones with different mutations, growth rates, antigen profiles and drug sensitivities coexist within the same mass, and selection under chemotherapy or radiation favours the resistant subclones. This is the molecular explanation of tumour progression (the acquisition of greater malignancy over time), and of the hard problem of drug resistance — a single-agent therapy selecting for a resistant subclone rather than curing the whole. The cancer stem cell hypothesis proposes that only a small subpopulation maintains tumour growth, which is one reason a residual tumour can regrow after an apparently complete microscopic resection.
Common mistakes
Watch outSaying an oncogene needs two hits. It needs one — oncogenes act by gain of function, and a single activating mutation in one allele is sufficient. Tumour suppressors need two — the loss is recessive at the level of the gene product.
Watch outSaying the Warburg effect is why cancers cannot make ATP. Cancer cells do respire; they simply run glycolysis alongside respiration. It is a metabolic reprogramming, not a respiratory failure, and it is the basis of PET imaging with fluorodeoxyglucose.
Watch outSaying angiogenesis means the tumour simply grows more blood vessels. It means the tumour secretes its own angiogenic factors (VEGF above all) and tilts the balance of the angiogenic regulators, so the vessel supply follows the tumour's own demand rather than the tissue's.
Check your understanding
How is a mutated TP53 different from a mutated KRAS in its contribution to cancer?
A patient has a breast cancer that secretes VEGF, which drives its own blood supply. Which hallmark is demonstrated, and what drug targets it?
Why does loss of a DNA repair gene produce many types of tumour over a lifetime, rather than one?
Multiple choice
Which mutation is most likely to require loss of both alleles in the same cell before a tumour develops?
Which hallmark explains how cancer cells obtain ATP despite hypoxia in the tumour mass?
Which pairing between the hallmark and its representative molecular mechanism is correct?
Which sequence best describes the progression of colorectal carcinoma according to the Vogelstein model?
A chemotherapy regimen selects for a resistant subclone of a tumour. Which property of tumours best explains this?
Summary and next
The hallmarks of cancer describe how a cell becomes a tumour: sustained growth signalling, evasion of suppression, escape from apoptosis, immortalisation, angiogenesis, invasion and metastasis, metabolic rewiring, immune evasion, genomic instability and inflammatory hijacking. Under the hallmarks sit the gene families — oncogenes (one activating hit), tumour suppressors (two hits), DNA repair genes and apoptosis regulators. The Vogelstein sequence shows these capabilities accumulating one mutation at a time, and the heterogeneity within any one tumour explains why single-agent therapies fail.
Next: where the mutations come from — chemical, physical and viral carcinogens, the initiator-promoter rules, and the inherited syndromes that predispose.